OTC · Biotechnology

Inventiva S.A. (IVEVF) Stock

$3.59 +0.00% OTC: IVEVF Healthcare

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other diseases.

Valuation

MetricValue
Price$3.59
Market Cap$499.23M
P/E Ratio-2.04
P/B Ratio-86.78
P/S Ratio120.51
EPS (TTM)$-1.90
52-Week High$5.75
52-Week Low$2.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE1220.69%
ROA-141.93%
ROCE-79.10%
Gross Margin35.07%
Operating Margin-3325.00%
Net Margin-8850.00%
Debt/Equity-2.10
Current Ratio3.16

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$12.0M$17.0M$15.0M$4.0M
Operating Profit$-52.0M$-57.0M$-103.0M$-98.0M$-133.0M
Net Profit$-50.0M$-54.0M$-110.0M$-184.0M$-354.0M
EPS$-1.27$-1.31$-2.43$-3.08$-1.90
Op Margin-1242.6%-468.9%-587.7%-662.6%-2965.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$122.0M$116.0M$70.0M$119.0M$250.0M
Total Liabilities$33.0M$71.0M$102.0M$226.0M$278.0M
Cash$87.0M$87.0M$27.0M$97.0M$99.0M
Borrowings$10.0M$35.0M$37.0M$54.0M$60.0M

Latest News

Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring Insider Monkey · Jul 15, 2026 Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound Simply Wall St. · Jul 12, 2026 European Equities Traded in the US as American Depositary Receipts Decline Friday MT Newswires · Jul 10, 2026 Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants GlobeNewswire · Jul 9, 2026 European Equities Traded in the US as American Depositary Receipts Rise Thursday MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-48.0M$-45.0M$-82.0M$-86.0M$-105.0M
Investing Cash Flow$-2.0M$8.0M$-8.0M$8.0M$-133.0M
Financing Cash Flow$25.0M$9.0M$5.0M$68.0M$-17.0M
Net Cash Flow$-19.0M$0$-60.0M$70.0M$3.0M
Free Cash Flow$-48.0M$-45.0M$-82.0M$-86.0M$-105.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.15
EV / EBITDA-3.75
FCF Yield-19.51%
Quick Ratio3.16
Interest Coverage-4.06
Return 1Y57.46%
Return 3Y-9.11%
Return 5Y-66.88%

Ownership

Insiders Held12.67%
Institutions Held49.53%
Institutions Float Held56.72%
Institutional HolderSharesReport Date
Artisan Partners Funds Inc.-Artisan International Small-Mid Fund637,8592026-03-31
-SSgA SPDR ETFS Europe I-State Street SPDR MSCI Europe Small Cap UCITS16,4092026-05-31
-SSgA SPDR ETFS Europe I-State Street SPDR MSCI World Small Cap UCITS 9,8432026-05-31
SPDR INDEX SHARES FUNDS-State Street SPDR Portfolio Europe ETF7,9232026-05-31
-SSgA SPDR ETFS Europe I-State Street SPDR MSCI All Country World Inve3,7042026-05-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIHLFAdcock Ingram Holdings Limited $3.50 +0.00% 9.77 $624.32M 5.43%
AMGXFAnGes, Inc. $0.36 +0.00% -3.40 $142.50M 0.00%
CCHWFColumbia Care Inc. $0.94 -21.71% -1.16 $521.35M 0.00%
CKDXFCeryvyn Therapeutics Limited $0.01 +0.00% 0.06 $13.68M 0.00%
CLAZFClaritas Pharmaceuticals, Inc. $0.00 — 0.00 $3659 0.00%

About Inventiva S.A.

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other diseases. Its leading drug candidate, Lanifibranor, has successfully completed Phase IIb clinical trials for NASH treatment. The company is also advancing Odiparcil, which has concluded Phase IIa clinical investigation for addressing MPS VI subtype disease. Furthermore, Inventiva maintains a pipeline of earlier-stage programs targeting oncology and other therapeutic areas. The firm has established strategic collaborations, including one with AbbVie for autoimmune diseases and another with Boehringer Ingelheim International GmbH to develop novel treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is headquartered in Daix, France.

Inventiva S.A. is headquartered in FR.

Inventiva S.A. (IVEVF) stock trades at $3.59 with a market capitalization of $499.23M. The stock is valued at a price-to-earnings (P/E) ratio of -2.04, price-to-book of -86.78, price-to-sales of 120.51. Over the past 52 weeks the stock has ranged between $2.28 and $5.75, and currently trades 37.6% below its 52-week high.

On profitability, Inventiva S.A. generates a return on equity (ROE) of 1220.69% — well above the market average, a sign of a high-quality business, return on capital employed of -79.10%, an operating margin of -3325.00%, a net profit margin of -8850.00%.

Official website: www.inventivapharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides